|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Besides p53DeltaE6 and p53beta, we identified p53zeta, p53delta and p53varepsilon, arising from alternative splicing of exon 6 and intron 9, respectively. p53 splice variants were present in 18 of 34 ovarian cancer cell lines (52.9%) and 134 of 245 primary ovarian cancers (54.7%). p53delta expression was associated with impaired response to primary platinum-based chemotherapy (P=0.032).
|
20101229 |
2010 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We present the apparent BRCA1-related, although mutation negative, breast and ovarian cancer patient who subsequently was confirmed to be TP53 c.817C>T (p.R273C) mutation carrier and discuss the importance of peri-diagnostic oncogenetic TP53 testing in early breast cancer cases.
|
21535297 |
2011 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In addition to mutation of BRCA1, mutation of the p53 gene is often found in patients with inherited breast and ovarian cancer syndrome.
|
20046879 |
2009 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
|
25316818 |
2014 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the TP53 codon 72 genotypes may be considered as a molecular marker, contributing to a genetic profile for ovarian cancer in women.
|
16542834 |
2006 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that intronic polymorphisms of the p53 gene modify the risk for ovarian cancer patients but not in carriers with BRCA1 or BRCA2 mutations.
|
10487631 |
1999 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Targeting HDAC4, HIF-1α and CREBZF may be considered in treatment of ovarian cancer with p53 and RAS mutations.
|
30867818 |
2019 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Therefore, current estimates of TP53 alterations in ovarian cancer may be inaccurate.
|
9579562 |
1998 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This represents the first attempt to define a genomic signature of TP53 mutation in ovarian cancer.
|
20504346 |
2010 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.
|
27189670 |
2016 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These findings indicate that a germ line p53 mutation significantly enhanced DMBA-induced ovarian tumor development and progression.
|
18234966 |
2008 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Loss of heterozygosity on chromosome 5q in ovarian cancer is frequently accompanied by TP53 mutation and identifies a tumour suppressor gene locus at 5q13.1-21.
|
8679443 |
1996 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
|
11595686 |
2001 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The aim of our study was to validate the use of PCR-RFLP techniques for the evaluation of p53 codon 72 and CYP1A1 gene polymorphisms in relation with ovarian cancer in a Romanian population and to evaluate gene-environment interaction in this context.
|
22395499 |
2012 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
It was speculated that p53 function was lost by TP53 germline mutation with the loss of a wild type allele induced by the chemotherapy against ovarian cancer, leading to the development of MDS.
|
15942101 |
2005 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Further analysis of TP53 gene mutations in ovarian cancer by geography could provide greater insights.
|
16907706 |
2006 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Does TP53 mutation promote ovarian cancer metastasis to omentum by regulating lipid metabolism?
|
23880140 |
2013 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
We have extended our LOH analysis of chromosome 3p to include 102 ovarian tumor specimens (29 and 73 samples were previously examined for LOH of chromosome 3p and 17 markers, respectively), using additional polymorphic markers, to assess the coordinate LOH of loci representing the three chromosome 3p minimal regions of deletions [von Hippel-Lindau syndrome (VHL), thyroid hormone receptor beta, and fragile histidine triad (FHIT)] and LOH of other important loci [tumor protein 53 (TP53), breast cancer 1 early onset (BRCA1), breast cancer 2 early onset, retinoblastoma 1, ornithine carbamoyltransferase, and androgen receptor] or somatic mutations in TP53.
|
12112314 |
2002 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
TP53 mutations and codon 72 genotype--impact on survival among ovarian cancer patients.
|
17488735 |
2007 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
However, Notch1 mRNA high expression is significantly associated with worsen OS in TP53 wild-type ovarian cancer patients, while it is significantly associated with better OS in TP53 mutation-type ovarian cancer patients.
|
26662955 |
2016 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Involvement of p53 gene in the allelic deletion of chromosome 17p in human ovarian tumors.
|
1776830 |
1992 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In one extreme case, we identified two independent TP53 mutations in ovary tumors and omentum/peritoneum metastases, respectively.
|
24221193 |
2014 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer.
|
25437714 |
2014 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutational spectrum of p53 mutations in primary breast and ovarian tumors.
|
15501075 |
2004 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Here, using pair-matched wild-type p53 CDDP-sensitive (OV2008) and -resistant (C13*) cells, and p53-compromised CDDP-resistant cells (A2780cp, OCC-1, OVCAR-3 and SKOV3), we have demonstrated (i) the existence of site-specific differences in phospho-Ser-Chk1 content between sensitive and resistant cells in response to CDDP; (ii) PPM1D, but not phosphoinositide-3-kinase-related kinase Ataxia Telangiectasia and Rad3 related protein (ATR), is important in the regulation of CDDP-induced Chk1 activation and OVCA cell chemosensitivity; (iii) PPM1D downregulation sensitizes resistant cells to CDDP primarily by activating Chk1 and p53.
|
21927021 |
2012 |